-
Something wrong with this record ?
Antidiabetic properties of S-allyl cysteine, a garlic component on Streptozotocin-induced diabetes in rats
Ganapathy Saravanan, Ponnusamy Ponmurugan, Gandhipuram Periyasamy Senthil Kumar, Thatchinamoorthi Rajarajan
Language English Country Czech Republic
Document type Tables
NLK
Free Medical Journals
from 2003 to 2013
Freely Accessible Science Journals
from 2003 to 2013
ROAD: Directory of Open Access Scholarly Resources
from 2002
- MeSH
- Garlic chemistry MeSH
- Cysteine analogs & derivatives isolation & purification therapeutic use MeSH
- Diabetes Mellitus drug therapy prevention & control MeSH
- Enzyme-Linked Immunosorbent Assay methods utilization MeSH
- Animal Experimentation MeSH
- Hypoglycemic Agents metabolism therapeutic use MeSH
- Blood Glucose drug effects MeSH
- Rats, Wistar MeSH
- Plant Extracts isolation & purification metabolism therapeutic use MeSH
- Streptozocin administration & dosage adverse effects MeSH
- Body Weight MeSH
- Transaminases blood drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Animals MeSH
- Publication type
- Tables MeSH
The present study was carried out to investigate the hypoglycaemic effect of S-allyl cysteine (SAC), a garlic component, on some biochemical parameters of STZ induced diabetic rats. STZ induced diabetic rats were treated with SAC at two different doses (100 mg/kg b.w. and 150 mg/kg b.w.) for 45 days. Treatment with SAC significantly decreased the levels of blood glucose, glycosylated hemoglobin, blood urea, serum uric acid, serum creatinine, and diminished activities of pathophysiological enzymes such as aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). The antihyperglycaemic nature of SAC is also evidenced from the improvement in the levels of plasma insulin and haemoglobin. Further, the results are comparable with glyclazide, an oral standard drug. A 150 mg/kg b.w. dose produced a better effect than a 100 mg dose. Thus, the present findings suggest that SAC may be considered as an effective therapeutic agent for the treatment of diabetes mellitus.
References provided by Crossref.org
Lit.: 56
- 000
- 00000naa 2200000 a 4500
- 001
- bmc09002363
- 003
- CZ-PrNML
- 005
- 20111210152436.0
- 008
- 091105s2009 xr e eng||
- 009
- AR
- 024 7_
- $a 10.32725/jab.2009.017 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Saravanan, Ganapathy
- 245 10
- $a Antidiabetic properties of S-allyl cysteine, a garlic component on Streptozotocin-induced diabetes in rats / $c Ganapathy Saravanan, Ponnusamy Ponmurugan, Gandhipuram Periyasamy Senthil Kumar, Thatchinamoorthi Rajarajan
- 314 __
- $a Department of Biochemistry, Centre for Biological Science, K.S.R. College of Arts and Science, Thokkavadi, Tiruchengode, Tamil Nadu, India, 637215
- 504 __
- $a Lit.: 56
- 520 9_
- $a The present study was carried out to investigate the hypoglycaemic effect of S-allyl cysteine (SAC), a garlic component, on some biochemical parameters of STZ induced diabetic rats. STZ induced diabetic rats were treated with SAC at two different doses (100 mg/kg b.w. and 150 mg/kg b.w.) for 45 days. Treatment with SAC significantly decreased the levels of blood glucose, glycosylated hemoglobin, blood urea, serum uric acid, serum creatinine, and diminished activities of pathophysiological enzymes such as aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). The antihyperglycaemic nature of SAC is also evidenced from the improvement in the levels of plasma insulin and haemoglobin. Further, the results are comparable with glyclazide, an oral standard drug. A 150 mg/kg b.w. dose produced a better effect than a 100 mg dose. Thus, the present findings suggest that SAC may be considered as an effective therapeutic agent for the treatment of diabetes mellitus.
- 650 _2
- $a česnek $x chemie $7 D005737
- 650 _2
- $a cystein $x analogy a deriváty $x izolace a purifikace $x terapeutické užití $7 D003545
- 650 _2
- $a rostlinné extrakty $x izolace a purifikace $x metabolismus $x terapeutické užití $7 D010936
- 650 _2
- $a hypoglykemika $x metabolismus $x terapeutické užití $7 D007004
- 650 _2
- $a diabetes mellitus $x farmakoterapie $x prevence a kontrola $7 D003920
- 650 _2
- $a experimenty na zvířatech $7 D032761
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a streptozocin $x aplikace a dávkování $x škodlivé účinky $7 D013311
- 650 _2
- $a ELISA $x metody $x využití $7 D004797
- 650 _2
- $a krevní glukóza $x účinky léků $7 D001786
- 650 _2
- $a transaminasy $x krev $x účinky léků $7 D000637
- 650 _2
- $a tělesná hmotnost $7 D001835
- 650 _2
- $a zvířata $7 D000818
- 655 _2
- $a tabulky $7 D020501
- 700 1_
- $a Ponmurugan, Ponnusamy
- 700 1_
- $a Kumar, Gandhipuram Periasamy Senthil
- 700 1_
- $a Rajarajan, Thatchinamoorthi
- 773 0_
- $w MED00012667 $t Journal of applied biomedicine $g Roč. 7, č. 3 (2009), s. 151-159 $x 1214-021X
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2009/03/06.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 8
- 990 __
- $a 20091105101214 $b ABA008
- 991 __
- $a 20110222093350 $b ABA008
- 999 __
- $a ok $b bmc $g 691534 $s 553433
- BAS __
- $a 3
- BMC __
- $a 2009 $b 7 $c 3 $d 151-159 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $a 2009-59/vtal
